HC Wainwright & Co. Reiterates Buy on AEON Biopharma, Maintains $18 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao reiterates a Buy rating on AEON Biopharma (AMEX:AEON) with an $18 price target.
May 06, 2024 | 10:44 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AEON Biopharma maintains a Buy rating from HC Wainwright & Co. with an $18 price target.
The reiteration of a Buy rating and maintenance of an $18 price target by a reputable analyst firm like HC Wainwright & Co. could positively influence investor sentiment towards AEON Biopharma, potentially driving up its stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100